FDA Approves Zevtera for Bacteremia, Skin and Skin Structure Infections, and Pneumonia
The FDA has approved Zevtera® injection (ceftobiprole medocaril sodium) for the treatment of adult patients with Staphylococcus aureus bloodstream infections, including those with:
o Right-sided infective endocarditis
o Adult patients with acute bacterial skin and skin structure infections (ABSSSI)
o Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).
- Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria.
- Zevtera is contraindicated in patients with a known history of severe hypersensitivity to Zevtera, or to other members of the cephalosporin class.
Source: Basilea Pharmaceutica Ltd
